COVID-19 disease severity to predict persistent symptoms: a systematic review and meta-analysis

Basit Öğe Kaydı
dc.authoridDIRICAN, EMRE/0000-0003-3550-1326
dc.contributor.authorDirican, Emre
dc.contributor.authorBal, Tayibe
dc.date.accessioned2024-09-18T20:13:26Z
dc.date.available2024-09-18T20:13:26Z
dc.date.issued2022
dc.departmentHatay Mustafa Kemal Üniversitesien_US
dc.description.abstractBackground: It is unclear, whether the initial disease severity may help to predict which COVID-19 patients at risk of developing persistent symptoms. Aim: The aim of this study was to examine whether the initial disease severity affects the risk of persistent symptoms in post-acute COVID-19 syndrome and long COVID. Methods: A systematic search was conducted using PUBMED, Google Scholar, EMBASE, and ProQuest databases to identify eligible articles published after January 2020 up to and including 30 August 2021. Pooled odds ratio (OR) and confidence intervals (CIs) were calculated using random effects meta-analysis. Findings: After searching a total of 7733 articles, 20 relevant observational studies with a total of 7840 patients were selected for meta-analysis. The pooled OR for persistent dyspnea in COVID-19 survivors with a severe versus nonsevere initial disease was 2.17 [95%CI 1.62 to 2.90], and it was 1.33 [95%CI 0.75 to 2.33] for persistent cough, 1.30 [95%CI 1.06 to 1.58] for persistent fatigue, 1.02 [95%CI 0.73 to 1.40] for persistent anosmia, 1.22 [95%CI 0.69 to 2.16] for persistent chest pain, and 1.30 [95%CI 0.93 to 1.81] for persistent palpitation. Conclusions: Contrary to expectations, we did not observe an association between the initial COVID-19 disease severity and common persistent symptoms except for dyspnea and fatigue. In addition, it was found that being in the acute or prolonged post-COVID phase did not affect the risk of symptoms. Primary care providers should be alert to potential most prevalent persistent symptoms in all COVID-19 survivors, which are not limited to patients with critical-severe initial disease.en_US
dc.identifier.doi10.1017/S1463423622000585
dc.identifier.issn1463-4236
dc.identifier.issn1477-1128
dc.identifier.pmid36352492en_US
dc.identifier.scopus2-s2.0-85141486577en_US
dc.identifier.scopusqualityQ1en_US
dc.identifier.urihttps://doi.org/10.1017/S1463423622000585
dc.identifier.urihttps://hdl.handle.net/20.500.12483/9190
dc.identifier.volume23en_US
dc.identifier.wosWOS:000880442400001en_US
dc.identifier.wosqualityQ4en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherCambridge Univ Pressen_US
dc.relation.ispartofPrimary Health Care Research and Developmenten_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectCOVID-19en_US
dc.subjectdisease severityen_US
dc.subjectpersistenten_US
dc.subjectsymptomsen_US
dc.titleCOVID-19 disease severity to predict persistent symptoms: a systematic review and meta-analysisen_US
dc.typeReview Articleen_US

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
Küçük Resim
İsim:
Tam Metin / Full Text
Boyut:
859.14 KB
Biçim:
Adobe Portable Document Format
İndir

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu